Cardiac magnetic resonance imaging in Pulmonary Arterial Hypertension

European Respiratory Review

Volumn 22, Issue 130, 2013, Pages 526-534

  Peacock, Andrew J ^a   Noordegraaf, Anton Vonk ^b  

^a Scottish Pulmonary Vascular Unit   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM;

CARDIOVASCULAR MAGNETIC RESONANCE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONTRAST ENHANCEMENT; ECHOCARDIOGRAPHY; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE VOLUME; HUMAN; LUNG ANGIOGRAPHY; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAGNETIC RESONANCE ANGIOGRAPHY; NON INVASIVE MEASUREMENT; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; COMPLICATION; DISEASE COURSE; ETIOLOGY; HYPERTENSION, PULMONARY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PREDICTIVE VALUE; TREATMENT OUTCOME;

DISEASE PROGRESSION; FAMILIAL PRIMARY PULMONARY HYPERTENSION; HUMANS; HYPERTENSION, PULMONARY; MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT;

EID: 84888812544     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00006313     Document Type: Review

References (52)

1. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis 2005; 16: 13-18.
2. Ho SY, Nihoyannopoulos P. Anatomy, echocardiography, and normal right ventricular dimensions. Heart 2006; 92: Suppl. 1, i2-i13.
3. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
4. van Wolferen SA, van de Veerdonk MC, Mauritz GJ, et al. Clinically significant change in stroke volume in pulmonary hypertension. Chest 2011; 139: 1003-1009.
5. van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007; 28: 1250-1257.
6. van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011; 58: 2511-2519.
7. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006; 174: 1034-1041.
8. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
9. Gaine S, Simonneau G. The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. Eur Respir Rev 2013; 22: 487-494.
10. Casanova C, Celli BR, Barria P, et al. The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur Respir J 2011; 37: 150-156.
11. Olsson LG, Swedberg K, Clark AL, et al. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J 2005; 26: 778-793.
12. Frost AE, Langleben D, Oudiz R, et al. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol 2005; 43: 36-39.
13. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
14. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60: 1192-1201.
15. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31: 202-208.
16. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129: 1313-1321.
17. Blyth KG, Groenning BA, Mark PB, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J 2007; 29: 737-744.
18. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870.
19. Vonk Noordegraaf A, Galie N. The role of the right ventricle in pulmonary arterial hypertension. Eur Respir Rev 2011; 20: 243-253.
20. Badano LP, Ginghina C, Easaw J, et al. Right ventricle in pulmonary arterial hypertension: haemodynamics, structural changes, imaging, and proposal of a study protocol aimed to assess remodelling and treatment effects. Eur J Echocardiogr 2010; 11: 27-37.
21. Grapsa J, O'Regan DP, Pavlopoulos H, et al. Right ventricular remodelling in pulmonary arterial hypertension with three-dimensional echocardiography: comparison with cardiac magnetic resonance imaging. Eur J Echocardiogr 2010; 11: 64-73.
22. Grapsa J, Gibbs JS, Dawson D, et al. Morphologic and functional remodeling of the right ventricle in pulmonary hypertension by real time three dimensional echocardiography. Am J Cardiol 2012; 109: 906-913.
23. Grapsa J, Gibbs JS, Cabrita IZ, et al. The association of clinical outcome with right atrial and ventricular remodelling in patients with pulmonary arterial hypertension: study with real-time three-dimensional echocardiography. Eur Heart J Cardiovasc Imaging 2012; 13: 666-672.
24. Kong D, Shu X, Pan C, et al. Evaluation of right ventricular regional volume and systolic function in patients with pulmonary arterial hypertension using three-dimensional echocardiography. Echocardiography 2012; 29: 706-712.
25. Bhave NM, Patel AR, Weinert L, et al. Three-dimensional modeling of the right ventricle from two-dimensional transthoracic echocardiographic images: utility of knowledge-based reconstruction in pulmonary arterial hypertension. J Am Soc Echocardiogr 2013; 26: 860-867.
26. Benza R, Biederman R, Murali S, et al. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 52: 1683-1692.
27. Bottini PB, Carr AA, Prisant LM, et al. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens 1995; 8: 221-228.
28. Grothues F, Smith GC, Moon JC, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002; 90: 29-34.
29. Grothues F, Moon JC, Bellenger NG, et al. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J 2004; 147: 218-223.
30. Saba TS, Foster J, Cockburn M, et al. Ventricular mass index using magnetic resonance imaging accurately estimates pulmonary artery pressure. Eur Respir J 2002; 20: 1519-1524.
31. Laffon E, Vallet C, Bernard V, et al. A computed method for noninvasive MRI assessment of pulmonary arterial hypertension. J Appl Physiol 2004; 96: 463-468.
32. Nogami M, Ohno Y, Koyama H, et al. Utility of phase contrast MR imaging for assessment of pulmonary flow and pressure estimation in patients with pulmonary hypertension: comparison with right heart catheterization and echocardiography. J Magn Reson Imaging 2009; 30: 973-980.
33. García-Alvarez A, Fernández-Friera L, Mirelis JG, et al. Non-invasive estimation of pulmonary vascular resistance with cardiac magnetic resonance. Eur Heart J 2011; 32: 2438-2445.
34. Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182: 252-260.
35. Yamada Y, Okuda S, Kataoka M, et al. Prognostic value of cardiac magnetic resonance imaging for idiopathic pulmonary arterial hypertension before initiating intravenous prostacyclin therapy. Circ J 2012; 76: 1737-1743.
36. Mauritz GJ, Kind T, Marcus JT, et al. Progressive changes in right ventricular geometric shortening and long-term survival in pulmonary arterial hypertension. Chest 2012; 141: 935-943.
37. Vogel-Claussen J, Skrok J, Shehata ML, et al. Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemodynamics in patients with pulmonary arterial hypertension. Radiology 2011; 258: 119-127.
38. van Wolferen SA, Marcus JT, Westerhof N, et al. Right coronary artery flow impairment in patients with pulmonary hypertension. Eur Heart J 2008; 29: 120-127.
39. Shehata ML, Harouni AA, Skrok J, et al. Regional and global biventricular function in pulmonary arterial hypertension: a cardiac MR imaging study. Radiology 2013; 266: 114-122.
40. Lumens J, Arts T, Marcus JT, et al. Early-diastolic left ventricular lengthening implies pulmonary hypertensioninduced right ventricular decompensation. Cardiovasc Res 2012; 96: 286-295.
41. Blyth KG, Groenning BA, Martin TN, et al. Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. Eur Heart J 2005; 26: 1993-1999.
42. McCann GP, Gan CT, Beek AM, et al. Extent of MRI delayed enhancement of myocardial mass is related to right ventricular dysfunction in pulmonary artery hypertension. AJR Am J Roentgenol 2007; 188: 349-355.
43. Sanz J, Dellegrottaglie S, Kariisa M, et al. Prevalence and correlates of septal delayed contrast enhancement in patients with pulmonary hypertension. Am J Cardiol 2007; 100: 731-735.
44. Junqueira FP, Macedo R, Coutinho AC, et al. Myocardial delayed enhancement in patients with pulmonary hypertension and right ventricular failure: evaluation by cardiac MRI. Br J Radiol 2009; 82: 821-826.
45. Freed BH, Gomberg-Maitland M, Chandra S, et al. Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson 2012; 14: 11.
46. Anagnostopoulos C, Georgakopoulos A, Pianou N, et al. Assessment of myocardial perfusion and viability by positron emission tomography. Int J Cardiol 2013; 167: 1737-1749.
47. Nekolla SG, Martinez-Moeller A, Saraste A. PET and MRI in cardiac imaging: from validation studies to integrated applications. Eur J Nucl Med Mol Imaging 2009; 36: Suppl. 1, S121-S130
48. Bokhari S, Raina A, Rosenweig EB, et al. PET imaging may provide a novel biomarker and understanding of right ventricular dysfunction in patients with idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging 2011; 4: 641-647.
49. McNeil K, Dunning J. Chronic thromboembolic pulmonary hypertension (CTEPH). Heart 2007; 93: 1152-1158.
50. Jeong HJ, Vakil P, Sheehan JJ, et al. Time-resolved magnetic resonance angiography: evaluation of intrapulmonary circulation parameters in pulmonary arterial hypertension. J Magn Reson Imaging 2011; 33: 225-231.
51. Swift AJ, Rajaram S, Condliffe R, et al. Pulmonary artery relative area change detects mild elevations in pulmonary vascular resistance and predicts adverse outcome in pulmonary hypertension. Invest Radiol 2012; 47: 571-577.
52. Sergiacomi G, Bolacchi F, Cadioli M, et al. Combined pulmonary fibrosis and emphysema: 3D time-resolved MR angiographic evaluation of pulmonary arterial mean transit time and time to peak enhancement. Radiology 2010; 254: 601-608.